Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Department of Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Cells. 2023 Apr 11;12(8):1135. doi: 10.3390/cells12081135.
The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.
为了确定最有效的 LuAD 靶向基因融合检测方法,我们分析了 210 例 NSCLC 选定的临床样本,比较了原位(荧光原位杂交 FISH、免疫组织化学 IHC)和分子(靶向 RNA 下一代测序 NGS、实时-PCR RT-PCR)方法。这些方法之间的总体一致性很高(>90%),靶向 RNA NGS 被证实是临床实践中识别基因融合最有效的技术,可同时在 RNA 水平上分析一大组基因组重排。然而,我们发现 FISH 对于那些组织学材料不足以进行分子检测的样本,以及那些 RNA NGS 面板未能识别融合的少数病例,是有用的,可以检测到靶向融合。我们得出的结论是,LuAD 的靶向 RNA NGS 分析可以准确检测 RTK 融合;然而,不应忽视标准方法,如 FISH,因为它们可以为 LuAD 的分子特征的完成,以及最重要的是,为确定适合靶向治疗的患者做出关键贡献。